Organization
David Bushnell
3 clinical trials
Clinical trial
A Phase 1/2 Trial Using AZEDRA and LUTATHERA in a Dosimetrically-determined Optimal Combination for Therapy of Selected Patients With Midgut Neuroendocrine TumorsStatus: Withdrawn, Estimated PCD: 2024-04-23
Clinical trial
A Phase 1, First-in-human Clinical Trial of [212Pb] VMT-alpha-NET Using a Forward Dosimetric Planning Technique to Treat Refractory or Relapsed Neuroendocrine TumorsStatus: Active (not recruiting), Estimated PCD: 2026-11-20
Clinical trial
Phase 1 Trial Using 131I MIBG and 90Y DOTATOC in a Dosimetrically Determined Optimal Combination for Therapy of Selected Patients With Midgut Neuroendocrine Tumors.Status: Active (not recruiting), Estimated PCD: 2025-12-01